Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Lymphoma, Primary Effusion 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1

Interventions

Etoposide 3Cyclophosphamide 3Vincristine 2Rituximab 2Prednisone 2Doxorubicin 2varlilumab 1prednylidene 1liposomal doxorubicin 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Endoscopy 1Electrocardiography 1Echocardiography 1Disulfides 1Cytarabine 1Carmustine 1CT-P10 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Primary Effusion × Ultrasonography × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡